Serving as a field-based extension of Medical Affairs, the Medical Science Liaison (MSL) will represent the Company and their monoclonal antibody, currently being investigated in B-cell malignancies ( lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)). The MSL will also handle pipeline products as their programs mature.
The MSL will build long term peer to peer relationships with thought leaders, payers and other stakeholders specializing in oncology treatment. The MSL will support the Company’s advancing biopharmaceutical clinical and research programs by delivering clinical, scientific, and technical education to the Hematology/Oncology community. The MSL is responsible for cultivating and maintaining collaborative relationships with influential members of the medical community to promote company, disease state and therapeutic awareness, in addition to serving as an advanced technical, scientific, and medical expert in the Hematology/Oncology community for the assigned region. The MSL is responsible for developing, coordinating and assuring implementation of the Company’s corporate, scientific, and clinical strategies with these thought leaders within academic, clinical, and healthcare organizations. These scientific exchanges will support and/or expand current therapeutic concepts, as well as ensure the safe and effective utilization of the Company’s product(s).